Aussies who are classified as 'moderate to high risk' and are aged between 18 and 64 now qualify for the immunisation.

More than 200,000 Australians who are immunocompromised will gain free access to the shingles vaccine in an expansion of a ...

The free shingles vaccination is now available to more people over 18 who are immunocompromised due to an underlying health condition or as a side effect of treatment. This free vaccine will now cover ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...

Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...

The US Food and Drug Administration (FDA) has approved the targeted interleukin (IL)-13 inhibitor lebrikizumab (Ebglyss) for ...

Today, where wellness is no longer a luxury but a necessity, Santa Clarita residents are discovering the transformative ...

which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without ...

Your roof is a major investment, and like any investment, you want it to last as long as possible. While roofs are designed to withstand years of weather and wear, their longevity largely depends on ...

Dr. Kwatra explains that for many patients with PN, reducing the itch directly leads to improvements in painful lesions.